Bristol-Myers Historical Balance Sheet

BMY -  USA Stock  

USD 68.15  0.58  0.84%

Trend analysis of Bristol-Myers Squibb balance sheet accounts such as Receivables of 9.2 B, Accounts Payable of 2.7 B or Total Assets of 127.8 B provides information on Bristol-Myers Squibb's total assets, liabilities, and equity, which is the actual value of Bristol-Myers Squibb to its prevalent stockholders. By breaking down trends over time using Bristol-Myers Squibb balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year. Financial Statement Analysis is much more than just reviewing and breaking down Bristol-Myers Squibb prevalent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bristol-Myers Squibb is a good buy for the upcoming year.
Continue to Trending Equities.

Search Historical Statements 


About Bristol-Myers Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Bristol-Myers Squibb at a specified time, usually calculated after every quarter, six months, or one year. Bristol-Myers Squibb Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Bristol-Myers Squibb and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Bristol-Myers currently owns. An asset can also be divided into two categories, current and non-current.

Bristol-Myers Squibb Balance Sheet Chart

Bristol-Myers Squibb Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Bristol-Myers Squibb uses and utilizes its capital. It also shows what exactly a company owns and owes.
Bristol-Myers Squibb Investments are fairly stable at the moment as compared to the past year. Bristol-Myers Squibb reported Investments of 1.72 Billion in 2020. Investments Current is likely to rise to about 1.5 B in 2021, whereas Inventories is likely to drop slightly above 1.8 B in 2021.

Total Assets

Total assets refers to the total amount of Bristol-Myers Squibb assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Bristol-Myers Squibb books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Major components are Cash and Equivalents; Investments; Goodwill and Intangible Assets; Property Plant and Equipment Net; Tax Assets and Trade and Non Trade Receivables.

Current Assets

Current assets of Bristol-Myers Squibb include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of Bristol-Myers Squibb. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.

Shareholders Equity

A principal component of the balance sheet; in addition to Total Liabilities and Total Assets; that represents the total of all stockholders' equity (deficit) items; net of receivables from officers; directors; owners; and affiliates of the entity which are attributable to the parent.

Total Liabilities

Deferred Income Tax is recorded on Bristol-Myers Squibb balance sheet and a result of income already earned and recognized for accounting, but not tax, purposes. Also, differences between tax laws and accounting methods can result in a temporary difference in the amount of income tax payable by a company. This difference is recorded on Bristol-Myers Squibb books as deferred income tax. Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Principal components are Total Debt; Deferred Revenue; Trade and Non Trade Payables; Deposit Liabilities; and Tax Liabilities.
Most accounts from Bristol-Myers Squibb balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Bristol-Myers Squibb current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.Bristol-Myers Squibb Investments are fairly stable at the moment as compared to the past year. Bristol-Myers Squibb reported Investments of 1.72 Billion in 2020. Investments Current is likely to rise to about 1.5 B in 2021, whereas Inventories is likely to drop slightly above 1.8 B in 2021.
 2018 2019 2020 2021 (projected)
Receivables5.35 B7.68 B8.5 B9.17 B
Inventories1.2 B4.29 B2.07 B1.8 B

Bristol-Myers Squibb balance sheet Correlations

Click cells to compare fundamentals

Bristol-Myers Squibb Account Relationship Matchups

Bristol-Myers Squibb balance sheet Accounts

201620172018201920202021 (projected)
Inventories1.24 B1.17 B1.2 B4.29 B2.07 B1.8 B
Receivables4.01 B5.09 B5.35 B7.68 B8.5 B9.17 B
Accounts Payable1.66 B2.25 B1.89 B2.44 B2.71 B2.73 B
Accumulated Other Comprehensive Income(2.5 B)(2.29 B)(2.76 B)(1.52 B)(1.84 B)(1.98 B)
Total Assets33.71 B33.55 B34.99 B129.94 B118.48 B127.83 B
Current Assets13.7 B14.85 B17.72 B29.35 B30.19 B25.78 B
Assets Non Current20 B18.7 B17.27 B100.59 B88.29 B95.26 B
Cash and Equivalents4.24 B5.42 B6.91 B12.35 B14.55 B15.69 B
Cash and Equivalents USD4.24 B5.42 B6.91 B12.35 B14.55 B15.69 B
Total Debt6.71 B7.96 B7.35 B46.73 B50.68 B54.68 B
Debt Current992 M987 M1.7 B3.35 B2.34 B2.52 B
Debt Non Current5.72 B6.97 B5.65 B43.39 B48.34 B52.15 B
Total Debt USD6.71 B7.96 B7.35 B46.73 B50.68 B54.68 B
Deferred Revenue1.94 B1.59 B1.31 B537 M483.3 M496.02 M
Shareholders Equity16.18 B11.74 B14.03 B51.6 B37.82 B31.53 B
Shareholders Equity USD16.18 B11.74 B14.03 B51.6 B37.82 B31.53 B
Goodwill and Intangible Assets8.26 B8.07 B7.63 B86.46 B73.79 B79.62 B
Inventory1.24 B1.17 B1.2 B4.29 B2.07 B2.06 B
Investments4.83 B3.87 B3.62 B3.81 B1.72 B1.76 B
Investments Current2.11 B1.39 B1.85 B3.05 B1.28 B1.47 B
Investments Non Current2.72 B2.48 B1.77 B767 M433 M444.39 M
Total Liabilities17.36 B21.7 B20.86 B78.25 B80.6 B86.96 B
Current Liabilities8.84 B9.56 B10.65 B18.3 B19.08 B16.26 B
Liabilities Non Current8.52 B12.14 B10.21 B59.94 B61.52 B66.38 B
Trade and Non Trade Payables1.66 B2.25 B1.89 B2.44 B2.71 B2.71 B
Property Plant and Equipment Net4.98 B5 B5.03 B6.25 B5.89 B6 B
Trade and Non Trade Receivables5.54 B6.3 B5.75 B7.68 B8.5 B7.38 B
Accumulated Retained Earnings Deficit33.51 B31.16 B34.06 B34.47 B21.28 B24.56 B
Tax Assets3 B1.61 B815 M510 M1.16 B1.39 B
Tax Liabilities1.12 B3.78 B19 M6.45 B5.41 B5.83 B

Bristol-Myers Squibb Investors Sentiment

The influence of Bristol-Myers Squibb's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Bristol-Myers. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - BMY

Bristol-Myers Squibb Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Bristol-Myers Squibb. What is your opinion about investing in Bristol-Myers Squibb? Are you bullish or bearish?
98% Bullish
2% Bearish

Pair Trading with Bristol-Myers Squibb

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol-Myers Squibb position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will appreciate offsetting losses from the drop in the long position's value.

Bristol-Myers Squibb Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol-Myers Squibb and Horizon Therapeutics. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Note that the Bristol-Myers Squibb information on this page should be used as a complementary analysis to other Bristol-Myers Squibb's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Bristol-Myers Stock analysis

When running Bristol-Myers Squibb price analysis, check to measure Bristol-Myers Squibb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol-Myers Squibb is operating at the current time. Most of Bristol-Myers Squibb's value examination focuses on studying past and present price action to predict the probability of Bristol-Myers Squibb's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol-Myers Squibb's price. Additionally, you may evaluate how the addition of Bristol-Myers Squibb to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
The market value of Bristol-Myers Squibb is measured differently than its book value, which is the value of Bristol-Myers that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol-Myers Squibb's value that differs from its market value or its book value, called intrinsic value, which is Bristol-Myers Squibb's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol-Myers Squibb's market value can be influenced by many factors that don't directly affect Bristol-Myers Squibb underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol-Myers Squibb's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol-Myers Squibb value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol-Myers Squibb's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.